-51%

est. 2Y upside i

HealthcareSeries A

Rank

#613

Sector

Mental Health AI / Digital Health

Est. Liquidity

~4Y

Data Quality

Data: Medium

Limbic presents a strong upside opportunity driven by its pioneering regulatory status (Class IIa UKCA medical device) and proven impact within the NHS, addressing a critical need in mental healthcare.

Last updated: March 10, 2026

Bull (32%)+300%

Limbic successfully expands into the US market, securing major health system partnerships and demonstrating strong ROI, leveraging its Class IIa medical device status and NHS success. Revenue scales to $100M+ by 2026, justifying a $400M+ valuation at 4x current.

Base (43%)+75%

Limbic continues its strong growth in the UK and makes steady progress in the US, but faces increased competition and slower adoption than anticipated. Revenue reaches $50M by 2026, leading to a $175M valuation.

Bear (25%)-80%

US expansion proves challenging due to regulatory hurdles and entrenched incumbents, while growth in the UK slows. A well-funded competitor emerges with a similar regulatory status, leading to pricing pressure. Revenue stalls at $25M, resulting in a down round to $20M, wiping out most common stock value given the $22M liquidation preference.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $22M in liquidation preferences ahead of common stock. In an exit at or below the estimated $100M valuation, common stock holders would see significantly reduced returns or nothing until the $22M preference is paid out.

Dilution Risk

high

As a Series A company expanding internationally, Limbic will likely require additional funding rounds (Series B, C, etc.) over the next 2-4 years, which will dilute existing equity holders.

Secondary Liquidity

none

There is no indication of an active secondary market or tender offers for Limbic's equity.

Questions to Ask at the Interview

Strategic questions based on Limbic's data — designed to show you've done your homework.

  • 1

    “Given Limbic's "world-first" Class IIa UKCA medical device status, how do you plan to navigate the FDA approval process for the US market, and what specific challenges do you anticipate from established healthcare IT providers like Epic or Cerner as you expand?”

  • 2

    “With current revenue around $17M and a large TAM, what are the key milestones and growth strategies Limbic is targeting to reach $100M+ in ARR over the next 2-3 years, particularly in the US market?”

  • 3

    “As a Series A company with significant funding, how is Limbic thinking about managing potential future dilution for employees, and what is the company's long-term vision for a liquidity event (e.g., IPO, acquisition) for common stock holders?”

Community

Valuation Sentiment

Our model estimates -51% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.